Immune-checkpoint inhibitors (ICIs) represent a novel therapeutic approach for numerous tumors. However, checkpoint blockade may be complicated by a unique spectrum of immune-related adverse events (irAEs), even severe (grade 3–4) in 5–24% of patients treated with ipilimumab and nivolumab [1]. Various neurological irAEs that involve the central and peripheral nervous systems have been reported, including polyneuropathy (3%), myasthenia gravis (0.2%) and necrotizing myositis, predominantly after nivolumab [2].

Source link